Skip to main content

Table 3 Prevalence of ESBL- Ec sensitive to additional antibiotics for each country visited a

From: High colonization rates of extended-spectrum β-lactamase (ESBL)-producing Escherichia coliin Swiss Travellers to South Asia– a prospective observational multicentre cohort study looking at epidemiology, microbiology and risk factors

  All countries (n = 157) India (n = 82) Bhutan (n = 15) Nepal (n = 41) Sri Lanka (n = 19)
AMC 58.6 59.8 73.3 56.1 47.4
PIP-TAZ 96.8 95.1 100.0 95.1 100.0
CEP 35.0 46.3 26.7 24.4 15.8
MEM 100.0 100.0 100.0 100.0 100.0
SXT 51.0 48.8 73.3 51.2 42.1
CIP 59.2 47.6 86.7 70.7 63.2
NF 98.1 98.8 93.3 97.6 100.0
FOS 99.4 100.0 100.0 97.6 100.0
AMK 95.5 96.3 100.0 95.1 89.5
TOB 82.2 76.8 100.0 87.8 79.0
COL 100.0 100.0 100.0 100.0 100.0
  1. Note: AMC, amoxicillin-clavulanate; PIP-TAZ, piperacillin-tazobactam; CEP, cefepime; MEM, meropenem; SXT, thrimetoprim-sulfamethoxazole; CIP, ciprofloxacin; NF, nitrofurantoin; FOS, fosfomycin; AMK, amikacin; TOB, tobramycin; COL, colistin.
  2. astated as %.